Phase III study evaluates addition of rituximab to ACVBP chemotherapy in low-risk diffuse large B-cell lymphoma

Source: Ann Oncol Area: News According to the results of a Phase III study, the addition of rituximab to ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone) chemotherapy leads to improved event-free survival (EFS) in younger patients with low-risk localised diffuse large B-cell lymphoma (DLBCL).   The authors note that controversy concerning the best treatment for localised low-risk DLBCL still remains, especially as chemo-immunotherapy has become the new standard. The LNH 93-01 study previously showed that young patients treated for localised low-risk DLBCL with the dose-intense ACVBP regimen plus consolidation had a longer EFS and overall survival (OS) than patients treated with three cycles of CHOP plus radiotherapy. The purpose of the current study was to evaluate whether the addition of rituximab to this could further improve outcomes.     A total of 223 treatment-naïve patients aged <66 years with stage I or II DLBCL and no adverse prognostic ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news